FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (RPRN) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Zikto taking award-winning Arki to Startup Nations Summit

Seoul, Korea 11/22/14 · Zikto taking award-winning Arki to Startup Nations Summit The...

The End of Transparency? Don't be a fraud target

Carrollton, TX 11/18/14 · - Over the years, progressive and productive societies...

Ultraseal international in finals of Midlands Business Awards 2015

Coventry, UK 11/14/14 · Ultraseal International, which exports to the automotive supply...

Arki: Hot New Wearable Tech Setting a Cracking Pace on Kickstarter

San Francisco, CA 11/14/14 · Update for November 21: 412 Backers $90,034 pledged...

UpWest Labs Unveils Details of Its Eighth Batch of Startups, Ranging From Genetics to 3D Design

Palo Alto, California 11/11/14 · Accelerator continues to support innovative entrepreneurs with its...

Modern Casting Impregnation helps automakers to avoid warranty claims on engines

Novi, MI 11/11/14 · Automakers can save money and avoid costly warranty...

The Evolution of Walking: Wearable Tech steps up to a new level

San Francisco, CA 11/11/14 · Arki: Finally Wearable Meets Fashion – Wearable technology is one of 2014’s...

GeneSegues Awarded $1 Million Phase II NIH/NCI Research Contract for Nanoencapsulated RNAi Cancer Therapeutic

MINNEAPOLIS, MN 11/10/14 · Highly Competitive NIH Program Validates Potential of GS-10...

More Than 400 .Onion Addresses Targeted as Part of Global Enforcement Action on Tor Network

WASHINGTON 11/07/14 · More Than 400 .Onion Addresses, Including Dozens of...

Learn about Wine in Your Pjs - A New Kind of Wine Class

SAUSALITO, CA. 11/04/14 · The Wine Key announced today it's first virtual...

XCEL Professional Services Has Made a Huge Change to Move Our Company Forward

Calgary, AB 11/04/14 · Introducing Rob Hay: The New President of XCEL...

Furries and Despair – two-man show at Canessa Gallery, November 7 Wild is beautiful

San Francisco, CA 11/03/14 · The show  "Furries and Despair" at Canessa Gallery...

Ristech Completes Acquisition of Kirtas Technologies Inc.

Victor, NY. 11/03/14 · With the acquisition of Kirtas Technology, Ristech increases...

Signed, sealed, delivered: Email best practices

San Francisco, CA 10/31/14 · Email is the original Web app. Born in...